Figure 1.

Expression and prognostic analysis of phosphorylated AKT (p-AKT) expression in diffuse large B-cell lymphoma (DLBCL). A: Representative immunohistochemistry (IHC) staining for p-AKT. B: Histogram of p-AKT immunohistochemistry scores in the DLBCL cohort. C: Scatter plot for nuclear p-AKT (Nuc-p-AKT) expression in DLBCL patients. The mean levels of Nuc-p-AKT expression in the germinal center B-cell–like (GCB) and activated B-cell–like (ABC) DLBCL subtypes are similar per IHC analysis. D: p-AKT^high expression (≥70% of tumor cells showing positive p-AKT nuclear staining) is associated with significantly poorer overall survival (OS) and progression-free survival in patients with DLBCL. E: Scatter plot for phosphatidylinositol 3-kinase (PI3K) expression in DLBCL patients. The p-AKT^high group has a significantly higher mean level of PI3K expression than the p-AKT^low group. F–H: Scatter plot for IL-6, Myc, and Bcl-2 expression by IHC in DLBCL patients. Compared with the p-AKT^low group, the p-AKT^high group has a significantly higher mean level of IL-6 expression in ABC-DLBCL, Myc expression in GCB-DLBCL, and Bcl-2 expression in both GCB- and ABC-DLBCL. Each dot in the scattered plots represents the expression level in one patient. ^∗P < 0.05, ^∗∗∗P < 0.001. Original magnification, ×60.